Related Experiment Video
Updated: Mar 1, 2026
04:40
Author Spotlight: Advancing Cancer Associated Thrombosis Research in Rodent Models
Published on: January 5, 2024
3.3K
Thrombotic microangiopathies and antineoplastic agents
Steven Grangé1, Paul Coppo2, 3
1Service de réanimation, CHU Charles-Nicolle, 1, rue de Germont, 76000 Rouen, France; Centre de référence des microangiopathies thrombotiques (CNR-MAT), AP-HP, 184, rue du Faubourg-Saint-Antoine, 75012 Paris, France.
Nephrologie & Therapeutique
|June 5, 2017
Summary
Cancer treatment can cause thrombotic microangiopathy, a serious condition. Early recognition and understanding of drug-induced versus cancer-related causes are crucial for improved patient outcomes.
Area of Science:
- Oncology
- Hematology
- Nephrology
Background:
- Thrombotic microangiopathy (TMA) is an increasing complication of cancer treatment.
- Awareness and use of anti-vascular endothelium growth factor (VEGF) drugs contribute to increased incidence.
- Distinguishing TMA from malignancy-induced TMA is critical for management and prognosis.
Purpose of the Study:
- To highlight the importance of recognizing cancer treatment-related TMA.
- To inform practitioners about antineoplastic agents causing TMA, their mechanisms, and management.
- To differentiate TMA caused by antineoplastic agents from that caused by malignancy.
Main Methods:
- Review of existing literature on chemotherapy-induced TMA.
- Analysis of mechanisms underlying TMA development with antineoplastic agents.
- Evaluation of diagnostic and management strategies for TMA in cancer patients.
Main Results:
- Chemotherapy-associated TMA has a historically poor prognosis.
- Understanding pathophysiology and exploring novel therapies like complement blockers may improve outcomes.
- Distinguishing between drug-induced and cancer-induced TMA is essential for appropriate treatment.
Conclusions:
- Cancer treatment-related TMA requires prompt recognition and tailored management.
- Further research into TMA pathophysiology and therapeutic interventions is warranted.
- Complement inhibitors show promise for treating certain forms of TMA.
Related Concept Videos
01:29Venous Thrombosis III: Interprofessional Care
423
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
423
01:10Drugs that Destabilize Microtubules
4.1K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.1K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
01:30Venous Thrombosis IV: Nursing Management
324
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
324
01:15Drugs that Stabilize Microtubules
2.8K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
01:30Venous Thrombosis I: Introduction
580
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
580